Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Peter Oppelt et al.|Clinical Cancer Research|2020Cited by 368
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaJonathan D. Schoenfeld, Robert I. Haddad, Glenn J. Hanna et al.|JAMA Oncology|2020Cited by 350
Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United StatesBrandon A. Mahal, Danielle N. Margalit, Paul J. Catalano et al.|Cancer Epidemiology Biomarkers & Prevention|2019Cited by 230
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J. Hanna, Robert I. Haddad, Anne O’Neill et al.|Clinical Cancer Research|2021Cited by 104
Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neckAlec Kacew, Glenn J. Hanna, Ethan Harris et al.|Oral Oncology|2020Cited by 30